mebeverine has been researched along with Colicky Pain in 10 studies
mebeverine: RN given refers to parent cpd; structure
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine." | 9.51 | Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. ( Abd-Elsalam, SM; Bahaa, MM; El-Haggar, SM; Hegazy, SK, 2022) |
| "We evaluated the effectiveness of an antispasmodic, mebeverine, in the treatment of childhood functional abdominal pain (FAP)." | 9.19 | Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial. ( Gholamrezaei, A; Pourmoghaddas, Z; Roohafza, H; Saneian, H, 2014) |
| "To assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment." | 7.88 | Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program "odyssey". ( Abdulhakov, SR; Akhmedov, VA; Akimov, AV; Andreev, DN; Batskov, SS; Eremnia, EY; Ivanchenko, DN; Khomeriki, NM; Krapivnaya, OV; Kucheravy, YA; Luzina, EV; Maev, IV; Onuchina, EV; Osipenko, MF; Shklyaev, AE; Simanenkov, VI; Sokolov, KA; Tonkih, YL; Tsukanov, VV; V'yuchnova, ES; Vasyutin, AV, 2018) |
| " The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine." | 5.51 | Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. ( Abd-Elsalam, SM; Bahaa, MM; El-Haggar, SM; Hegazy, SK, 2022) |
| "We evaluated the effectiveness of an antispasmodic, mebeverine, in the treatment of childhood functional abdominal pain (FAP)." | 5.19 | Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial. ( Gholamrezaei, A; Pourmoghaddas, Z; Roohafza, H; Saneian, H, 2014) |
| "To assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment." | 3.88 | Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program "odyssey". ( Abdulhakov, SR; Akhmedov, VA; Akimov, AV; Andreev, DN; Batskov, SS; Eremnia, EY; Ivanchenko, DN; Khomeriki, NM; Krapivnaya, OV; Kucheravy, YA; Luzina, EV; Maev, IV; Onuchina, EV; Osipenko, MF; Shklyaev, AE; Simanenkov, VI; Sokolov, KA; Tonkih, YL; Tsukanov, VV; V'yuchnova, ES; Vasyutin, AV, 2018) |
| "Patients identified at community pharmacies, using mebeverine as a proxy for IBS, were administered a questionnaire regarding (1) the Rome II criteria for IBS, (2) predominant type of stool during complaints, (3) severity of symptoms (abdominal pain and discomfort), (4) generic and disease-specific quality of life, (5) current health status (utilities), and (6) loss of productivity." | 3.73 | Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. ( Goettsch, WG; Herings, RM; Smout, AJ; ten Berg, MJ; van den Boom, G, 2006) |
| " Very few adverse events were noted and a causal relationship with the study medications was judged as improbable or definitely unrelated." | 2.68 | A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. ( Ceuppens, M; Hendrickx, B; Mayeur, S; Meeus, MA; Rosillon, D; Van Outryve, M, 1995) |
| "Mebeverine is a musculotropic agent that potently blocks intestinal peristalsis." | 2.50 | Role of antispasmodics in the treatment of irritable bowel syndrome. ( Annaházi, A; Róka, R; Rosztóczy, A; Wittmann, T, 2014) |
| "Acute abdominal pain is a common presentation to the emergency department (ED)." | 1.62 | Acute lead poisoning: a diagnostic challenge in the emergency department. ( Gopinath, B; Jamshed, N; Kappagantu, V; Mathew, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Haggar, SM | 1 |
| Hegazy, SK | 1 |
| Abd-Elsalam, SM | 1 |
| Bahaa, MM | 1 |
| Gopinath, B | 1 |
| Kappagantu, V | 1 |
| Mathew, R | 1 |
| Jamshed, N | 1 |
| Maev, IV | 1 |
| Kucheravy, YA | 1 |
| Tsukanov, VV | 1 |
| Eremnia, EY | 1 |
| Andreev, DN | 1 |
| Abdulhakov, SR | 1 |
| Akhmedov, VA | 1 |
| Batskov, SS | 1 |
| Vasyutin, AV | 1 |
| V'yuchnova, ES | 1 |
| Ivanchenko, DN | 1 |
| Luzina, EV | 1 |
| Krapivnaya, OV | 1 |
| Onuchina, EV | 1 |
| Osipenko, MF | 1 |
| Simanenkov, VI | 1 |
| Tonkih, YL | 1 |
| Khomeriki, NM | 1 |
| Shklyaev, AE | 1 |
| Akimov, AV | 1 |
| Sokolov, KA | 1 |
| Annaházi, A | 1 |
| Róka, R | 1 |
| Rosztóczy, A | 1 |
| Wittmann, T | 1 |
| Pourmoghaddas, Z | 1 |
| Saneian, H | 1 |
| Roohafza, H | 1 |
| Gholamrezaei, A | 1 |
| ten Berg, MJ | 1 |
| Goettsch, WG | 1 |
| van den Boom, G | 1 |
| Smout, AJ | 1 |
| Herings, RM | 1 |
| Mearin, F | 1 |
| Il'chenko, AA | 1 |
| Bystrovskaia, EV | 1 |
| Selezneva, EIa | 1 |
| Deliukina, OV | 1 |
| Drozhzhina, IuV | 1 |
| Van Outryve, M | 1 |
| Mayeur, S | 1 |
| Meeus, MA | 1 |
| Rosillon, D | 1 |
| Hendrickx, B | 1 |
| Ceuppens, M | 1 |
| Grillage, MG | 1 |
| Nankani, JN | 1 |
| Atkinson, SN | 1 |
| Prescott, P | 1 |
2 reviews available for mebeverine and Colicky Pain
| Article | Year |
|---|---|
Role of antispasmodics in the treatment of irritable bowel syndrome.
Topics: Abdominal Pain; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal | 2014 |
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
5 trials available for mebeverine and Colicky Pain
| Article | Year |
|---|---|
Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; Irritabl | 2022 |
Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial.
Topics: Abdominal Pain; Adolescent; Child; Female; Follow-Up Studies; Humans; Male; Pain Management; Parasym | 2014 |
[Chronic abdominal pain syndrome in biliary pathology].
Topics: Abdominal Pain; Adult; Cholelithiasis; Chronic Disease; Female; Gallbladder Diseases; Humans; Male; | 2007 |
A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Colonic Diseases, Functional; Cross-Over | 1995 |
A randomised, double-blind study of mebeverine versus dicyclomine in the treatment of functional abdominal pain in young adults.
Topics: Abdominal Pain; Adolescent; Adult; Child; Cyclohexanecarboxylic Acids; Dicyclomine; Double-Blind Met | 1990 |
3 other studies available for mebeverine and Colicky Pain
| Article | Year |
|---|---|
Acute lead poisoning: a diagnostic challenge in the emergency department.
Topics: Abdominal Pain; Acute Disease; Adult; Anemia; Antiemetics; Chelating Agents; Chlordiazepoxide; Choli | 2021 |
Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program "odyssey".
Topics: Abdominal Pain; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Parasympatholytics; Phen | 2018 |
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
Topics: Abdominal Pain; Chronic Disease; Constipation; Cost of Illness; Diarrhea; Female; Health Status; Hea | 2006 |